One Of The NFL's Best Players Will Lose $700,000 Because He Took A Banned Fertility Drug
Getty Images
The suspension will cost the NFL's sack leader $706,000 in lost salary according to Mike Chappell of IndyStar.com.
That is a huge penalty if Mathis' excuse is to be believed.
Mathis' agent, Hadley Englehard, was a guest on ESPN Radio's "Mike & Mike" and explained that the drug was prescribed by a doctor to help his client's wife become pregnant and wondered why some players are given therapeutic-use exemptions and his client is being treated so harshly.
"He used [the drug] for a short period of time, 10-12 days," said Englehard. "Once he found out his wife was pregnant he stopped taking it. He has the leftover medication."
Still, Mathis never consulted with the NFL and went solely on the word of the doctor that Clomid would not cause a problem with NFL drug testing.
In addition, there is scientific evidence that Clomid increases testosterone levels in men, which would be performance enhancing, even if it that was not the original intent.
It's great that Mathis' wife was able to get pregnant. However, to ask for leniency only after the positive test for a banned substance puts the NFL in a tough situation that would create a dangerous precedent.
- As Ilya Sutskever announces OpenAI exit, here’s a quick recap of his involvement in Sam Altman's firing last year
- DHFL scam, simplified: Here’s all about the Dheeraj Wadhawan case — allegedly India’s biggest banking loan fraud ever
- India-UK trade pact: Work in progress to resolve pending issues
- 5 most colourful mountains in the world
- Vivo takes the top spot in India: Top smartphone brands in Q1 2024
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market